Vaxart Inc

Vaxart’s new $25 million share‑sale plan with Lincoln Park Capital fuels its oral flu vaccine research, giving flexible capital while keeping full control over timing and quantity of stock.

Vaxart’s oral flu and norovirus vaccines spark biotech buzz, promising gut‑activated immunity and breakthrough data for lactating women and infants—watch its Nasdaq growth.

Vaxart’s oral flu vaccines spark gut‑immune responses, but the stock’s volatile performance and negative earnings highlight a speculative investment risk.

Vaxart’s pioneering oral flu vaccine tech sparks biotech buzz and investor interest—learn how gut‑stimulated immunity could reshape flu prevention and boost the company’s growth.

Vaxart’s oral flu vaccine tech sparks biotech buzz—despite volatile shares, its gut‑immune strategy and 3x book‑value valuation signal long‑term promise.

Vaxart’s stock dives 64%, negative P/E, and weak earnings flag deep financial risk for the oral flu‑vaccine biotech, urging investors to watch its struggle for profitability.

Vaxart’s oral flu vaccines aim to trigger gut‑based immune responses, offering a novel vaccine approach amid stock price struggles and negative earnings.

Vaxart’s oral flu vaccine redefines flu prevention, delivering gut‑activated immune protection worldwide via direct‑to‑consumer sales, boosting biotech innovation.

Vaxart’s oral flu vaccine could revolutionize flu prevention, but the biotech’s shaky finances and regulatory hurdles keep investors wary.

Vaxart’s oral flu vaccine could revolutionize flu prevention, yet the biotech’s steep financial struggles and regulatory hurdles keep its future uncertain.